Test Price
1,600 AED✅ Home Collection Available
IDH1 & IDH2 Mutation Analysis in UAE | 1600 AED | 2026 DHA Guidelines
تحليل طفرات جيني IDH1 وIDH2 في الإمارات | 1600 درهم | معتمد من هيئة الصحة بدبي
Executive Summary & الملخص التنفيذي
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 15189 Accredited Sanger Sequencing Processing with dual-strand bidirectional verification.
Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection and VIP Mobile Phlebotomy for tumor tissue procurement coordination.
يوفر تحليل طفرات جيني IDH1 وIDH2 تشخيصاً جزيئياً دقيقاً بنسبة حساسية تشخيصية تبلغ 99.9% عبر معالجتنا المعتمدة بموجب شهادة الأيزو 15189. نقدم خدمة تنسيق سحب عينات نسيج الورم المنزلي المدفوعة مسبقاً عبر نظام النقل المبرد المعتمد، بالإضافة إلى استشارة طبية هاتفية بعد صدور النتائج لتفسيرها سريرياً من قبل أطبائنا المعتمدين من هيئة الصحة بدبي.
Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation by DHA-licensed molecular pathologists.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731
Test Overview & Clinical Utility
The IDH1 and IDH2 Mutation Analysis is a high-precision molecular diagnostic test that detects somatic point mutations in the isocitrate dehydrogenase 1 and 2 genes using gold-standard Sanger Sequencing technology. This analysis is essential for the diagnosis, prognosis, and targeted therapy stratification of gliomas, acute myeloid leukemias, chondrosarcomas, and select cholangiocarcinomas. يُعد هذا التحليل الجزيئي أساسياً في تشخيص وتصنيف الأورام الدبقية وسرطانات الدم النخاعية الحادة وتوجيه خطط العلاج الموجه بدقة عالية.
| Feature | Our Test — Sanger Sequencing | Closest Alternative — NGS Panel |
|---|---|---|
| Diagnostic Precision | 99.9% per-base accuracy with bidirectional sequencing confirmation | 98–99% depending on coverage depth; variant calls require orthogonal confirmation |
| Mutation Coverage | Full coding region of IDH1 (exon 4, codon R132) and IDH2 (exon 4, codons R140, R172) | Broader multi-gene panel; may miss low-frequency IDH2 variants if depth insufficient |
| Turnaround Time | 7–8 Days | 14–21 Days |
| Cost in UAE | 1600 AED | 2500–4000 AED |
| Clinical Applicability | Focused, clinically actionable results aligned with WHO CNS5 and ELN 2026 guidelines | Incidental findings may require additional genetic counseling resources |
Physician Insight & Safety Protocol
Dr. PRABHAKAR REDDY
DHA License: 61713011 | Consultant Molecular Pathologist
As a molecular pathologist, I want to emphasize that an IDH1 or IDH2 mutation result is not merely a laboratory value — it is a pivotal biomarker that redefines your diagnosis and opens the door to precision oncology. These mutations carry profound prognostic significance, particularly in gliomas where IDH-mutant status confers a markedly more favorable outcome. However, every result must be correlated with your complete clinical picture, imaging studies, and histopathological findings; no single genetic test should dictate your care pathway in isolation.
⚠ Medication Safety Warning
Do not discontinue prescribed medication without consulting your doctor.
IDH inhibitor therapy (e.g., ivosidenib, enasidenib, vorasidenib) must only be initiated, adjusted, or discontinued under direct oncologist supervision. Abrupt cessation may lead to disease progression or differentiation syndrome.
⚠ Patient Safety — Exclusion Criteria & Emergency Red Flags
Exclusion Criteria for Tumor Tissue Sampling:
- Uncorrected coagulopathy (INR > 1.5, Platelets < 50,000/µL)
- Active systemic infection or sepsis
- Inaccessible tumor site precluding safe biopsy
- Patient on dual antiplatelet therapy without bridging plan
- Pregnancy with contraindication to anesthesia (per pre-test information protocol)
ER Red Flags — Seek Immediate Medical Attention:
- Uncontrolled bleeding at biopsy site beyond 24 hours
- Sudden neurological deterioration (severe headache, vision loss, seizure)
- Signs of infection: fever > 38.5°C, purulent discharge, spreading erythema
- Acute dyspnea or chest pain (potential thromboembolic event)
- Severe abdominal pain or compartment syndrome post-procedure
Patient FAQ & Clinical Guidance
1. What is the IDH1 & IDH2 Mutation Analysis test used for?
The IDH1 and IDH2 mutation analysis identifies specific genetic mutations in tumor tissue to guide accurate cancer diagnosis, predict patient prognosis, and determine eligibility for targeted IDH-inhibitor therapies. This test is clinically indicated for gliomas (brain tumors), acute myeloid leukemia (AML), chondrosarcomas, and cholangiocarcinomas where IDH mutational status directly influences WHO grading classification and therapeutic decision-making.
يُستخدم تحليل طفرات جيني IDH1 وIDH2 لتحديد الطفرات الجينية المحددة في نسيج الورم بهدف توجيه التشخيص الدقيق للسرطان وتوقع مسار المرض وتحديد الأهلية لعلاجات مثبطات IDH الموجهة.
2. How is the performed and what sample is required?
This analysis requires a formalin-fixed paraffin-embedded tumor tissue sample obtained through a clinically indicated biopsy or surgical resection procedure coordinated by your treating physician. Our laboratory provides VIP coordination for sample procurement, cold-chain transport, and processing under ISO 15189-accredited protocols, ensuring specimen integrity from the point of collection through to DNA extraction and Sanger sequencing analysis.
يتطلب هذا التحليل عينة من نسيج الورم مثبتة بالفورمالين ومضمنة بالبارافين، يتم الحصول عليها عبر خزعة أو استئصال جراحي تحت إشراف الطبيب المعالج، مع تنسيق النقل المبرد المعتمد لضمان سلامة العينة.
3. What is the turnaround time, cost, and insurance coverage in the UAE?
Results are delivered within 7 to 8 working days at a total cost of 1600 AED, with direct insurance billing verification available exclusively through our dedicated WhatsApp support line. We accept all major UAE medical insurance providers and offer a streamlined pre-authorization process; for uninsured patients, transparent self-pay options with itemized invoicing are provided to ensure complete financial clarity before testing commences.
تُصدر النتائج خلال 7 إلى 8 أيام عمل بتكلفة إجمالية قدرها 1600 درهم إماراتي، مع إمكانية التحقق من التغطية التأمينية المباشرة عبر خط واتساب المخصص لدينا، بالإضافة إلى خيارات دفع شفافة للمرضى غير المؤمن عليهم.
UAE Regulatory Compliance & Accreditation
• Federal Decree-Law No. 41 of 2024 (Art. 87) — Mandatory genetic testing quality standards and patient consent protocols
• CDS Law 2026 — Minors' genetic testing requires authorized guardian consent and genetic counseling referral
• UAE PDPL — All patient genomic data encrypted and stored within UAE sovereign data infrastructure
• ISO 9001:2015 Certified — Cert: INT/EGQ/2509DA/3139
• DHA Facility License: 9834453
• MOHAP Molecular Genetics Testing License — Full compliance with 2026 updated schedule
Schedule Your IDH1 & IDH2 Mutation Analysis Today
Home Collection: 8 AM – 11 PM | Results: 7–8 Days | 1600 AED | DHA-Approved Laboratory
WhatsApp: +971 54 548 8731
Prescription required. Not applicable for surgery and pregnancy cases or individuals planning to travel abroad.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians